At our practice, we are dedicated to providing comprehensive care to our patients
Preclinical and clinical safety data includes [5] : No evidence of mutagenic activity, chromosomal aberrations, or micronucleus formation in genotoxicity studies 6-month chronic oral administration studies in rats showed no toxicological concerns 9-month studies in cynomolgus monkeys revealed general safety Six human clinical trials spanning 0.25 mg to 30 mg doses for up to 6 months No serious adverse events or withdrawals related to AOD9604 intake No anti-AOD9604 antibodies detected, indicating low immunogenic potential No changes in vital signs, physical examinations, electrocardiograms, or safety-related laboratory parameters Research Applications A Quick Review AOD9604 is a peptide compound that has shown potential in research related to lipid metabolism, energy balance, and tissue regeneration
The appear to be the same as what the doctor uses, but a different brand
[1] Unlike the folic acid derivative leucovorin, folic acid is not clinically useful in offsetting the action of folate reductase inhibitors because it requires the enzyme dihydrofolate reductase for activation
The Endocrine Society publishes clinical practice guidelines on obesity management that include sections on incretin-based therapies
